“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”

BACKGROUND: ROS1 fusion is an infrequent, but attractive target for therapy in patients with metastatic non- small-cell lung cancer. In studies on mainly late-stage disease, the prevalence of ROS1 fusions is about 1–3%. In early-stage lung cancer ROS1 might also provide a fruitful target for neoadju...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyrbekk, Anne Pernille Harlem, Warsame, Abdirashid Ali, Suhrke, Pål, Ludahl, Marianne Odnakk, Moe, Joakim Oliu, Eide, Inger Johanne Zwicky, Lund-Iversen, Marius, Brustugun, Odd Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224579/
https://www.ncbi.nlm.nih.gov/pubmed/37237384
http://dx.doi.org/10.1186/s13000-023-01357-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224579/
https://www.ncbi.nlm.nih.gov/pubmed/37237384
http://dx.doi.org/10.1186/s13000-023-01357-1

Ejemplares similares